Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr. Reddy’s Explores Drug Delivery Options For In-House Molecule

This article was originally published in PharmAsia News

Executive Summary

Hyderabad, India-based Dr. Reddy's announced Feb. 8 an agreement with drug delivery firm SkyePharma to conduct a feasibility study of a Dr. Reddy's product utilizing two of the London-based firm's drug delivery systems. Dr. Reddy's will fund the study and pay SkyePharma an up-front fee. SkyePharma was unwilling to share further details on the agreement with PharmAsia News. Indian firms such as Dr. Reddy's are increasingly turning to novel drug delivery systems to strengthen their products' market position (PharmAsia News, Feb. 7, 2008)

You may also be interested in...



Indian Drug Makers Move To Novel Drug Delivery Systems

India is expected to ride the drug industry trend toward new ways to deliver new drugs to patients, a growing segment of the pharmaceutical industry. Many Indian drug makers are working on novel drug discovery systems, already comprising nearly six percent of the Indian market. Revenues from NDDS products are expected to generate 29 percent annual growth in India, compared with 17 percent by the industry at large. Much of the new focus by drug makers results from a shrinking number of innovative drugs coming on the market at the same time blockbuster drugs lose their patent protections. (Click here for more

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC143429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel